Home Page: Cancer Treatment Reviews

Time 2021-05-29 16:12:24

Web Name: Home Page: Cancer Treatment Reviews

WebSite: http://www.cancertreatmentreviews.com

ID:179955

Keywords:

Page,Home,Cancer,

Description:

Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?Timothée Olivier, Eugenio Fernandez, Intidhar Labidi-Galy, Pierre-Yves Dietrich, Veronica Rodriguez-Bravo, Giulia Baciarello, Karim Fizazi, Anna PatrikidouDOI: https://doi.org/10.1016/j.ctrv.2021.102204Cancer Treatment Reviews, Vol. 97Open Access NRAS mutant melanoma: towards better therapiesTijana Randic, Ines Kozar, Christiane Margue, Jochen Utikal, Stephanie KreisDOI: https://doi.org/10.1016/j.ctrv.2021.102238Publication stage: In Press Journal Pre-ProofPreviewFull-Text HTMLPDFxCutaneous melanoma is a highly aggressive malignancy with a growing incidence accounting for around 290 000 cases (1.6%) of all newly diagnosed cancers worldwide and more than 60 000 deaths in 2018 [1,2]. Exogenous and endogenous risk factors cause malignant transformation of melanocytes, which are neural crest-derived and melanin-producing cells [2-4]. Exposure to ultraviolet (UV) radiation and a history of sunburns are the main carcinogens responsible for the onset of melanoma and other skin cancers, causing the highest tumor mutational burden (TMB) in somatic cells of all cancer types (median TMB of melanoma 14.4 mutations/Mb, squamous cell carcinoma 45.2, and basal cell carcinoma 47.3 mutations/Mb) [5-7].Adenocarcinoma Spectrum Lesions of the Lung: Detection, Pathology and Treatment StrategiesL Succony, DM Rassl, AP Barker, FM McCaughan, RC RintoulDOI: https://doi.org/10.1016/j.ctrv.2021.102237Publication stage: In Press Journal Pre-ProofPreviewFull-Text HTMLPDFxWorldwide, lung cancer outcomes remain poor. Lung cancer is often asymptomatic in its early stages therefore many patients present with advanced stage disease for which treatment with curative intent is often not possible. Lung cancer has the mortality rate of all cancers, responsible for 2.09 million deaths globally per annum[1].Breast reconstruction and radiation therapy: an expert Delphi Consensus statements and critical reviewIcro Meattini, Carlotta Becherini, Marco Bernini, Elisabetta Bonzano, Carmen Criscitiello, Fiorenza De Rose, Maria Carmen De Santis, Antonella Fontana, Pierfrancesco Franco, Oreste Davide Gentilini, Lorenzo Livi, Bruno Meduri, Silvana Parisi, Nadia Pasinetti, Agnese Prisco, Nicola RoccoDOI: https://doi.org/10.1016/j.ctrv.2021.102236Publication stage: In Press Journal Pre-ProofPreviewFull-Text HTMLPDFxBreast cancer is the most common cause of cancer-related deaths for women worldwide with an overall increasing trend of prevalence and mortality rate [1,2]. Breast conserving surgery (BCS) plus radiation therapy (RT) or mastectomy have shown comparable oncological outcomes in early-stage breast cancer and are considered standard of care treatment to be offered to patients based on the specific disease presentation [3,4]. Although both interventions are valid options, mastectomy should not be regarded as equal to breast conservation [5].Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancerF.J. Crowley, R.E. O'Cearbhaill, D.C. CollinsDOI: https://doi.org/10.1016/j.ctrv.2021.102225Publication stage: In Press Journal Pre-ProofPreviewFull-Text HTMLPDFxCervical cancer is the number one cause of gynecological cancer death worldwide[1]. It is the fourth most frequent cancer in women globally, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million)[2]. It is estimated that 604,127 patients were diagnosed with the disease worldwide in 2020[1].Fig 1.Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E. Geyer Jr, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine PiccartDOI: https://doi.org/10.1016/j.ctrv.2021.102229Publication stage: In Press Journal Pre-ProofOpen AccessPreviewFull-Text HTMLPDFxThe HER2-positive early breast cancer (EBC) treatment landscape evolved steadily over two decades [1]. Pivotal adjuvant trials [2-6] transformed standards-of-care, catalysing transition from chemotherapy to chemotherapy-plus-trastuzumab (significantly improving disease-free/overall survival [DFS/OS]). Neoadjuvant treatment opened two major avenues: increased pathological complete response Immunotherapy in non-small cell lung cancer harbouring driver mutationsAlfredo Addeo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah, Alex FriedlaenderDOI: https://doi.org/10.1016/j.ctrv.2021.102179Vol. 96Published online: March 18, 2021Open AccessFull-Text HTMLPDFBevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L ChinotDOI: https://doi.org/10.1016/j.ctrv.2020.102017Vol. 86Published online: March 26, 2020Open AccessFull-Text HTMLPDFHow did lomustine become standard of care in recurrent glioblastoma?Michael Weller, Emilie Le RhunDOI: https://doi.org/10.1016/j.ctrv.2020.102029Vol. 87Published online: May 4, 2020Open AccessFull-Text HTMLPDFAvelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practicePetros Grivas, Neeraj Agarwal, Sumanta Pal, Arash Rezazadeh Kalebasty, Srikala S. Sridhar, Jodi Smith, Geeta Devgan, Cora N. Sternberg, Joaquim BellmuntDOI: https://doi.org/10.1016/j.ctrv.2021.102187Vol. 97Published online: March 22, 2021Open AccessFull-Text HTMLPDFRisk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E. Geyer Jr, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine PiccartDOI: https://doi.org/10.1016/j.ctrv.2021.102229Publication stage: In Press Journal Pre-ProofPublished online: May 19, 2021Open AccessFull-Text HTMLPDF Access this journal on ScienceDirect Visit ScienceDirect to see if you have access via your institution. Journal Access Articles are available from 1974 to the present. Access to abstracts is complimentary. Access to full-text is limited to print subscribers. Activate Online Access About Cancer Treatment Reviews Cancer Treatment Reviews (Incorporating Evidence-based Oncology) is an international review journal that will keep both the clinician and researcher abreast of modern concepts and developments in cancer treatment research through the publication of state of the art, authoritative reviews; evidence-based reviews (using a priori defined selection process to identify key articles from the literature and reviewing them in the form of a structured abstract, evidence summary and commentary); and systematic reviews.These journal metrics provide authors with extra insight into the journals and help them in their journal selection process when submitting an article for publication. We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.

TAGS:Page Home Cancer 

<<< Thank you for your visit >>>

Hot Websites